Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 14, Issue 2, 1999, Pages 113-119

  Leigh, Bryan R ^a,c   Burke, Patricia A ^a   Hong, Angela M ^a   O'Donnell, Robert T ^a   Howell, Lydia P ^b   Miers, Laird A ^a   DeNardo, Gerald L ^a   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL DESTRUCTION; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOREACTIVITY; KAPOSI SARCOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PUNCH BIOPSY; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY; RADIOIODINATION; RADIOISOTOPE DISTRIBUTION; RECEPTOR AFFINITY; SARCOMA CELL; SPINDLE CELL; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 0032964463     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1999.14.113     Document Type: Article

References (27)

1. Berson A, Quivey J, Harris J, and Wara W. Radiation therapy for AIDS-related Kaposi's sarcoma. International Journal of Radiation Oncology, Biology, Physics 1990;19:569-575.
2. Morris A and Valley A. Overview of the management of AIDS-related Kaposi's sarcoma. Annals of Pharmacotherapy 1996;30:1150-1163.
3. Hellstrom I, Beaumier P, and Hellstrom K. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proceedings of the National Academy of Sciences 1996;83:7059-7063.
4. Hellstrom I, Horn D, Linsley P, Brown J, Brankovan V, and Hellstrom K. Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Research 1986;46:3917-3923.
5. Marken J, Bajorath J, Edward C, Farr A, Schieven G, Hellstrom I, Hellstrom K, and Aruffo A. Membrane topology of the L6 antigen and identification of the protein epitope recognized by the L6 monoclonal antibody. Journal of Biological Chemistry 1994;269:7397-7401.
6. DeNardo S, O'Grady L, Richman C, Goldstein D, O'Donnell R, DeNardo D, Kroger L, Lamborn K, Hellstrom K, Hellstrom I, and DeNardo G. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Research 1997;17:1745-1751.
7. DeNardo S, Richman C, Goldstein D, Shen S, Salako Q, Kukis D, Meares C, Yuan A, Welborn J, and DeNardo G. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Research 1997;17:1735-1744.
8. DeNardo S, Mirick G, Kroger L, O'Grady L, Erickson K, Yuan A, Lamborn K, Hellstrom I, Hellstrom K, and DeNardo G. The biologic window for chimeric L6 radioimmunotherapy. Cancer 1994;73:1023-1032.
9. Lunardi-Iskandar Y, Gill P, Lam V, Zeman R, Michaels F, Mann D, Reitz M, Kaplan M, Bememan Z, Carter D, Bryant J, and Gallo R. Isolation and characterization of an immortal neoplastic cell line (KS Y-1) from AIDS-associated Kaposi's sarcoma. Journal of the National Cancer Institute 1995;87:974-981.
10. Hellstrom I, Garrigues U, Lavie E, and Hellstrom K. Antibody-mediated killing of human tumor cells by attached effector cells. Cancer Research 1988;48:624-627.
11. Liu A, Robinson R, Hellstrom K, Murray E, Chang C, and Hellstrom I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proceedings of the National Academy of Sciences 1987;84:3439-3443.
12. Howell L, DeNardo S, Levy N, Lund J, and DeNardo G. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: A comparative study. The International Journal of Biological Markers 1999;10:129-135.
13. Hunter W and Greenwood F. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 1962;194:495-496.
14. Adams G, DeNardo S, Amin A, Kroger L, DeNardo G, Hellstrom I, and Hellstrom K. Comparison of the pharmacokinetics in mice and the biological activity of murine L6 and human-mouse chimeric ch-L6 antibody. Antibody, Immunoconjugates, and Radiopharmaceuticals 1992;5:81-95.
15. Wofsy C and Goldstein B. Interpretation of Scatchard plots for aggregating receptor systems. Mathematical Biosciences 1992;112:115-154.
16. Beaumier P, Neuzil D, Yang H, Noll E, Kishore R, Eary J, Krohn K, Nelp W, Hellstrom K, and Hellstrom I. Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. Journal of Nuclear Medicine 199827:824-828.
17. Scatchard G. The attraction of proteins for small molecules and ions. Annals of the New York Academy of Sciences 1949;51:660-672.
18. Stelzer K and Griffin T. A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma. International Journal of Radiation Oncology, Biology, Physics 1993;27:1057-1061.
19. Hosono M, Endo K, Hosono M, Kobayashi H, Shirato M, Sakahara H, Ueda R, and Konishi J. Treatment of small-cell lung cancer xenografts with iodine-131-anti-neural cell adhesion molecule monoclonal antibody and evaluation of absorbed dose in tissue. Journal of Nuclear Medicine 1994;35:296-300.
20. King D, Turner A, Farnsworth A, Adair J, Owens R, Pedley R, Baldock D, Proudfoot K, Lawson A, Beeley N, Millar K, Millican T, Boyce B, Antoniw P, Mountain A, Begent R, Shochat D, and Yarranton G. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Research 1994;54:6176-6185.
21. Goodman G, Hellstrom I, Brodzinsky L, Nicaise C, Kulander B, Hummel D, and Hellstrom K. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. Journal of Clinical Oncology 1990;8:1083-1092.
22. Ziegler L, Palazzolo P, Cunningham J, Janus M, Itoh K, Hayakawa K, Hellstrom I, Hellstrom K, Nicaise C, Dennin R, and Murray J. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. Journal of Clinical Oncology 1992;10:1470-1478.
23. DeNardo S, O'Grady L, Richman C, and DeNardo G. Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6. In: L. Ceriani (ed.), Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis, pp. 203-211, New York: Plenum Press. 1994.
24. Wahl A, Donaldson K, Fairchild C, Lee F, Foster S, Demers G, and Galloway D. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Medicine 1996;2:72-79.
25. Welles L, Seville MW, Lietzau J, Pluda JM, Wyvill KM, Fuerstein I, Figg WD, Lush R, Odom, J, Wilson W, Fajardo, MT, Humphrey RW, Feigal E, Tuck D, Steinberg SM, Broder S, and Yarchoan R. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. Journal of Clinical Oncology 1998;16:1112-1121.
26. DeNardo S, Kukis D, Kroger L, O'Donnell R, Lamborn K, Miers L, DeNardo D, Meares C, and DeNardo G. Synergy of Taxol and radioimmunotherapy with. yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proceedings of the National Academy of Sciences 1997;94:4000-4004.
27. DeNardo S, Richman C, Kukis D, Shen S, Lamborn K, Miers L, Kroger L, Perez E, and DeNardo G. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol. Anticancer Research 1999;18: 4011-4018.